

Caelus Health and AMC Amsterdam signs exclusive Option Agreement on ongoing Fecal Microbiota Transplant (FMT) studies

Amsterdam – Over the recent years it has been demonstrated that alterations in intestinal microbiota are associated with obesity and insulin resistance. Caelus has been founded based on the groundbreaking work with fecal Transplant studies in the AMC. This has compounded in her first clinical products in the field of metabolic syndrome and diabetes II.

The newly signed option agreement gives Caelus access to new microbiota based products in the field of a.o. NASH (Non Alcoholic Steato-Hepatitis) and NAFLD (Non Alcoholic Fatty Liver Disease). FMT Studies in these new areas with unmet need are on-going in the Amsterdam Medical Centre and will strongly fuel the product pipeline of Caelus Health

In the recent past FMT-studies at AMC have demonstrated the effects of infusing intestinal microbiota from lean donors to male recipients with metabolic syndrome on the recipients' microbiota composition and glucose metabolism. It was concluded that 6 weeks after infusion of microbiota from lean donors, insulin sensitivity of recipients increased along with levels of butyrate-producing intestinal microbiota. Caelus is developing *E. hallii* as its first product to enhance insulin sensitivity.

The Option Agreement that was signed today today facilitates Caelus Health in expanding its product portfolio of microbiota-based therapeutic products. At the Academic Medical Center (AMC) in Amsterdam ongoing FMT-studies are performed in close collaboration with the Wageningen University, a leading Institute for Microbiota research.

Luc Sterkman MD, CEO of Caelus states: *"We are delighted to announce this Agreement which allows Caelus access to a new range of strains which may be very relevant as source of new Microbiota-based interventions. We expect to take such leads quickly into the clinic and develop new products for prevention or early treatment of disorders in the cardiometabolic field"*

Caelus Health is an Amsterdam-based biotech company. Caelus is dedicated to the commercialisation of functional food and pharmaceutical products for the prevention and early treatment of cardio-metabolic diseases. Based on the strong correlation between the intestinal microbiome and health, the company is developing an entirely new class of microbiota-based therapeutics for the reduction of insulin resistance and prevention of Type 2 Diabetes Mellitus (T2DM) in people with metabolic syndrome (MetS). The first product is now in clinical phase of development and is based on Eubacterium hallii. Life Sciences Fund Amsterdam (LSFA) is the founding investor.

AMC, the Academic Medical Center (AMC) is one of the foremost research institutions in the Netherlands, as well as one of its largest hospitals. Over 7000 people work at AMC to provide integrated patient care, fundamental and clinical scientific research, and teaching. The AMC complex houses among others the university hospital and the faculty of medicine of UvA as well as the Emma Children's Hospital and the Netherlands Institute for Neuroscience. A number of biotech companies (some of which are AMC spin-offs) are also located on the premises. This concentration of expertise makes the centre a breeding ground for fruitful scientific collaboration.

For more information please contact:

Caelus Health: LGW Sterkman; l.sterkman@caelushealth.com; tel: +31-6-22979249